DETERMINING RAPIDITY THAT EXOGENOUS P SUPPRESSES DAYTIME LH PULSE FREQUENCY

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 P抑制白天LH（和GnRH）脉冲频率的速度尚不清楚。我们建议使用随机、交叉、安慰剂对照研究进一步评估这一点。用E2预处理的排卵妇女将在GCRC中进行24小时采样研究。取样10小时后，口服微粒化孕酮（100 mg p.o.）将给予混悬液或安慰剂混悬液（根据随机化）。在随后的月经周期中，受试者将接受另一项与第一项相同的GCRC研究（包括E2预处理），但根据交叉设计，将口服孕酮换成安慰剂，反之亦然。我们将评估孕酮对LH频率的急性影响，次要终点为平均LH、LH脉冲幅度和平均FSH。我们假设，在卵泡期对成年女性给予P（0600 h）将导致12小时内白天LH（和推论GnRH）脉冲频率的明显抑制。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The rapidity with which P suppresses daytime LH (and by inference GnRH) pulse frequency is unknown. We propose to assess this further using a randomized, cross-over, placebo-controlled study. Ovulatory women pretreated with E2 will undergo a 24-h sampling study in the GCRC. After 10 h of sampling, either oral micronized progesterone (100 mg p.o.) suspension or placebo suspension will be administered (according to randomization). During a subsequent menstrual cycle, subjects will undergo another GCRC study identical to the first (including pretreatment with E2) except that oral progesterone will be exchanged for placebo or vice versa in accordance with the crossover design. We will assess the acute effects of progesterone on LH frequency, with secondary endpoints being mean LH, LH pulse amplitude, and mean FSH. We hypothesize that administration of P (at 0600 h) to adult women during the follicular phase will result in a demonstrable suppression of daytime LH (and by inference GnRH) pulse frequency within 12 hours.